The synergistic effect between phages and Ceftolozane/Tazobactam in Pseudomonas aeruginosa endotracheal tube biofilm

Emerg Microbes Infect. 2024 Dec;13(1):2420737. doi: 10.1080/22221751.2024.2420737. Epub 2024 Nov 17.

Abstract

Although an increased effectiveness has been suggested when phages and antibiotics are combined, this approach has not been tested against a mature biofilm on an endotracheal tube (ETT) surface. This study evaluated the effect of short- and long-term combined phage-antibiotic therapy in a control of a mature biofilm on an ETT surface. Pseudomonas aeruginosa strains, including susceptible and resistant clinical samples, were used to develop the ETT biofilm. Biofilm was treated with 108PFU/mL of phage_2, phage_18 or 5 μg/mL of ceftolozane/tazobactam, alone or in combination with phages. The sequential combination of the two different phages and ceftolozane/tazobactam was also tested. Biofilm viability was assessed after short (2, 4, 24 h) and long-(48, 72 h) term treatment exposure using colony forming unit measurement. For long-term exposition, a new treatment shot was added every 24 h. In the sequential combination, the phage type was switched at 24 h of treatment. Regarding the susceptible strains, the treatments had limited antibiofilm effect after 2, 4 and 24 h. After 48 and 72 h, administering phages alone had no effect on biofilm viability, indicating the emergence of phage-resistant phenotypes. Nonetheless, the combined phage-antibiotic treatment reduced the biofilm viability in about 5-log, whilst antibiotic alone reduced in about 3-log. The sequential combination of phages and antibiotic reduced the biofilm viability in about 6-log. With respect to the resistant strains, no antibiofilm activity was observed regarding the treatment arms. The combination of phages and ceftolozane/tazobactam showed a synergism strain-dependent, being more apparent in susceptible strains.

Keywords: Phage-therapy; biofilm; ceftolozane/tazobactam; endotracheal tube; pseudomonas aeruginosa.

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Biofilms* / drug effects
  • Cephalosporins* / pharmacology
  • Humans
  • Intubation, Intratracheal
  • Microbial Sensitivity Tests
  • Phage Therapy
  • Pseudomonas Infections* / microbiology
  • Pseudomonas Infections* / therapy
  • Pseudomonas Phages / physiology
  • Pseudomonas aeruginosa* / drug effects
  • Pseudomonas aeruginosa* / physiology
  • Pseudomonas aeruginosa* / virology
  • Tazobactam* / pharmacology

Substances

  • Tazobactam
  • Cephalosporins
  • Anti-Bacterial Agents
  • ceftolozane, tazobactam drug combination

Grants and funding

This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brazil (CAPES) - Finance Code 001 and ARISTOS program (European Union's Horizon Europe under the MSCA agreement 101081334) to VCO; Pro-Rectory of Research and Innovation at the University of São Paulo, Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP 2018/09757-0, 2019/13271-9, 2020/03405-5, 2021/00510-5 and 2022/01992-6), and National Council for Scientifc and Technological Development (CNPq 405622/2018-0; 314787/2021-6; and 443300/2023-2) to EW; CB 06/06/0028/CIBER de enfermedades respiratorias (Ciberes - Ciberes is an initiative of ISCIII), 2.603/IDIBAPS, and ICREA Academy award to AT; 2021 SGR 01148/Generalitat de Catalunya and SEPAR grant (1536-2024) to LFB. Funders did not play any role in project design, data collection, data analysis, interpretation, or writing of the paper.